Diffuse Hemispheric Glioma H3 G34-mutant
📧 Sign up to get email alerts when something new happens for Diffuse Hemispheric Glioma H3 G34-mutant.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant [Phase 2]
Phase 2 clinical trial exploring ribociclib with everolimus or with temozolomide for high-grade gliomas and related diffuse gliomas; recruit…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma [Phase 1]
Phase 1 trial evaluating a neoantigen-targeted ppDC vaccine for diffuse hemispheric glioma with H3 G34 mutation.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating a combination of ADI-PEG 20, temozolomide, and radiotherapy for newly diagnosed high-grade glioma, …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of Avutometinib and Defactinib in malignant brain tumors is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Study of 177Lu-PSMA-617 in People With Gliomas [Phase 1]
A Phase 1 clinical trial is evaluating 177Lu-PSMA-617 in patients with gliomas and related subtypes and is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma [Phase 1]
Phase 1 clinical trial update evaluating intrathecal azacitidine in combination with nivolumab for recurrent high-grade glioma. The study is…
-
CLINICAL_TRIALS research · 2025-04-25Clinical Trial Update: 5G-EMERALD: Amivantamab in Malignant Brain Tumours [Phase 1]
A Phase 1 clinical trial of amivantamab for malignant brain tumors, including glioblastoma and related gliomas, is currently recruiting in t…